TY - JOUR
T1 - Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma
AU - Luo, Liu Ying
AU - Shan, Shannon J.C.
AU - Elliott, Marc B.
AU - Soosaipillai, Antoninus
AU - Diamandis, Eleftherios P.
PY - 2006/2/1
Y1 - 2006/2/1
N2 - Purpose: Preliminary data suggest that hK11 is a novel serum biomarker for prostate and ovarian cancer. To examine the enzymatic characteristics of hK11, we purified and functionally characterized native hK11 from seminal plasma. Experimental Design: hK11 was purified from seminal plasma by immunoaffinity chromatography and characterized by kinetic analysis, electrophoresis, Western blots, and mass spectrometry. Results: hK11 is present in seminal plasma at concentrations ranging from 2 to 37 μg/mL. Using immunoaffinity chromatography and reverse-phase high-performance liquid chromatography, we purified hK11 to homogeneity. In seminal plasma, hK11 is present as a free enzyme of ∼40 kDa. About 40% of hK11 is enzymaticalty active, whereas the rest is inactivated by internal cleavage after Arg156 (Genbank accession no. AF164623), which generates two peptides of ∼20 kDa, connected by internal disulfide bonds. Purified hK11 possesses trypsin-like activity and cleaves synthetic peptides after arginine but not lysine residues. It does not cleave chymotrypsin substrates. Antithrombin, α1- antichymotrypsin, α2-antiplasmin, and α1- antitrypsin have no effect on hK11 activity and do not form complexes with hK11 in vitro. The strongest inhibitor, APMSF, completely inhibited hK11 activity at a concentration of 2.5 mmol/L. Aprotinin and an hK11-specific monoclonal antibody inhibited hK11 activity up to 40%. Plasmin is a strong candidate for cleaving hK11 at Arg156. Conclusion: This is the first report on purification and characterization of native hK11. We speculate that hK11, along with other kallikreins, proteases, and inhibitors, participates in a cascade enzymatic pathway responsible for semen liquefaction after ejaculation.
AB - Purpose: Preliminary data suggest that hK11 is a novel serum biomarker for prostate and ovarian cancer. To examine the enzymatic characteristics of hK11, we purified and functionally characterized native hK11 from seminal plasma. Experimental Design: hK11 was purified from seminal plasma by immunoaffinity chromatography and characterized by kinetic analysis, electrophoresis, Western blots, and mass spectrometry. Results: hK11 is present in seminal plasma at concentrations ranging from 2 to 37 μg/mL. Using immunoaffinity chromatography and reverse-phase high-performance liquid chromatography, we purified hK11 to homogeneity. In seminal plasma, hK11 is present as a free enzyme of ∼40 kDa. About 40% of hK11 is enzymaticalty active, whereas the rest is inactivated by internal cleavage after Arg156 (Genbank accession no. AF164623), which generates two peptides of ∼20 kDa, connected by internal disulfide bonds. Purified hK11 possesses trypsin-like activity and cleaves synthetic peptides after arginine but not lysine residues. It does not cleave chymotrypsin substrates. Antithrombin, α1- antichymotrypsin, α2-antiplasmin, and α1- antitrypsin have no effect on hK11 activity and do not form complexes with hK11 in vitro. The strongest inhibitor, APMSF, completely inhibited hK11 activity at a concentration of 2.5 mmol/L. Aprotinin and an hK11-specific monoclonal antibody inhibited hK11 activity up to 40%. Plasmin is a strong candidate for cleaving hK11 at Arg156. Conclusion: This is the first report on purification and characterization of native hK11. We speculate that hK11, along with other kallikreins, proteases, and inhibitors, participates in a cascade enzymatic pathway responsible for semen liquefaction after ejaculation.
UR - http://www.scopus.com/inward/record.url?scp=32944456614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32944456614&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-1696
DO - 10.1158/1078-0432.CCR-05-1696
M3 - Article
C2 - 16467084
AN - SCOPUS:32944456614
SN - 1078-0432
VL - 12
SP - 742
EP - 750
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3 I
ER -